Estimating dementia risk using multifactorial prediction models

JAMA Network Open

2023-06-13

(Press-News.org) About The Study: The findings of this study suggest that current dementia risk scores have limited clinical utility for estimation of 10-year dementia risk. Further research is needed to develop more accurate algorithms for estimation of dementia risk.

Authors: Mika Kivimäki, Ph.D. of University College London, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi: 10.1001/jamanetworkopen.2023.18132)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.18132?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061323

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

END

ELSE PRESS RELEASES FROM THIS DATE:

Content analysis of emoji and emoticon use in clinical texting systems

2023-06-13

About The Study: This study found that when clinicians use emoji and emoticons in secure clinical texting systems, these symbols function primarily to convey new and interactionally salient information. These results suggest that concerns about the professionalism of emoji and emoticon use may be unwarranted. Authors: Colin M. E. Halverson, Ph.D., of the Indiana University School of Medicine in Indianapolis, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi: 10.1001/jamanetworkopen.2023.18140) Editor’s Note: Please ...

People who preserve ‘immune resilience’ live longer, resist infections

2023-06-13

Embargoed by Nature Communications until 10 a.m. Central Time on Tuesday, June 13 SAN ANTONIO (June 13, 2023) — Researchers from The University of Texas Health Science Center at San Antonio, working with collaborators in five countries, today revealed that the capacity to resist or recover from infections and other sources of inflammatory stress — called “immune resilience” — differs widely among individuals. The researchers developed a unique set of metrics to quantify the level ...

Improving potential stem cell-based treatments for patients with Type 1 Diabetes

2023-06-13

Following encouraging results from pre-clinical research and a recent clinical trial on stem cell-based treatments for patients with Type 1 diabetes, researchers are now working on maximizing the function and potential of stem cell-based treatments for future application in patients. More than 8 billion people worldwide live with Type 1 diabetes (T1D) according to recent estimates. In T1D, the so-called beta cells in the pancreas do not make enough of the hormone insulin due to the destruction of beta-cells by the immune system leading to blood sugar levels rising above normal levels. Over time, T1D can lead to severe organ damage. There is no cure ...

Lung and heart stem cell research paves way for new COVID-19 treatments

2023-06-13

Researchers have used heart and lung stem cells infected with the virus that causes COVID-19 to better understand how the disease impacts different organs, paving the way for more targeted treatments. The research, co-led by Murdoch Children’s Research Institute and the Peter Doherty Institute for Infection and Immunity (Doherty Institute), found the responses to SARS-CoV-2 varied significantly depending on the cell type, allowing the team to identify effective anti-viral drugs to treat infection in heart and lung cells. The findings were published in the 10th anniversary edition of Stem Cell Reports. Murdoch ...

Four state policies linked to growth of telehealth at mental health facilities

2023-06-13

Four state policies introduced during the COVID-19 pandemic to spur expansion of telehealth were associated with expansion of such services by mental health facilities, but growth of telehealth was lower among facilities in counties with the greatest proportion of Black residents, according to a new RAND Corporation study. Expansion of telehealth also was lower among facilities that accepted Medicaid or the Children’s Health Insurance Program, two government insurance programs that aid primarily lower-income Americans, according to the study. The findings show that disparities in access to mental health care persisted even as ...

Only 1 in 4 adolescent treatment facilities offer buprenorphine for opioid use disorder

2023-06-13

Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a new study. Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in access to evidence-based addiction treatment among young people. Published in JAMA, this study was supported by the National Institute on Drug Abuse (NIDA) and the National Center for Advancing Translational Sciences ...

Mapping the development of infection-fighting immune cells

2023-06-13

LA JOLLA (June 13, 2023)—The immune system protects the body from invaders, such as bacteria, viruses, or tumors, with its intricate network of proteins, cells, and organs. Specialized immune cells, called cytotoxic T cells, can develop into short-lived effector cells that kill infected or cancerous cells within our bodies. A small portion of those effector cells remain after an infection and become longer-lived memory cells, which “remember” infections and respond when infections reappear. ...

Pew funds 22 scientists exploring pressing biomedical questions

2023-06-13

PHILADELPHIA—The Pew Charitable Trusts today announced the 22 researchers selected to join the Pew Scholars Program in the Biomedical Sciences. These early-career scientists will receive four years of funding to spearhead innovative studies exploring human health and medicine. “From vaccine development to treatments for complex diseases, biomedical research is foundational to solving some of the world’s greatest health challenges,” said Susan K. Urahn, Pew’s president and CEO. “Pew is thrilled to welcome this new class of researchers and support their efforts to advance scientific knowledge and improve human ...

5 Pew-Stewart Scholars selected to advance cutting-edge cancer research

2023-06-13

PHILADEPHIA—The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2023 class of the Pew-Stewart Scholars Program for Cancer Research. These early-career scientists will receive four-year grants to explore new horizons in cancer development, diagnosis, and treatment. This class marks the 10th year the Alexander and Margaret Stewart Trust has partnered with Pew to build a legacy of innovative cancer research. “Cancer is one of the most pressing challenges facing biomedical researchers today,” said Susan K. Urahn, Pew’s president and CEO. “Pew ...

Pew funds 10 Latin American scientists pursuing biomedical research

2023-06-13

PHILADELPHIA – The Pew Charitable Trusts today announced the 2023 class members of the Pew Latin American Fellows Program in the Biomedical Sciences. These 10 postdoctoral fellows from seven Latin American countries—Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Uruguay—will receive two years of funding to conduct research in laboratories throughout the United States. The fellows will work under the mentorship of prominent biomedical scientists, including an alum of the Pew Scholars Program in the Biomedical Sciences. “Scientific ...

Tirzepatide improves blood sugar control in children aged 10-17 years with type 2 diabetes inadequately controlled on existing therapies (SURPASS-PEDS trial)

Estimating dementia risk using multifactorial prediction models

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: